Anne Mobergslien

  • Research assistent Civil engineer
  • +47 22781411
 

Author network for Anne Mobergslien by COREMINE medical


Publications 2016

Mobergslien A, Peng Q, Vasovic V, Sioud M (2016)
Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth
Oncotarget, 7 (46), 75940-75953
DOI 10.18632/oncotarget.12445, PubMed 27713158

Sioud M, Nyakas M, Sæbøe-Larssen S, Mobergslien A, Aamdal S, Kvalheim G (2016)
Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine
Case Rep Med, 2016, 9639585
DOI 10.1155/2016/9639585, PubMed 27504122

Publications 2015

Mobergslien A, Sioud M (2015)
A facile method for interfering with off-target silencing mediated by the sense strand
Methods Mol Biol, 1218, 293-300
DOI 10.1007/978-1-4939-1538-5_18, PubMed 25319659

Mobergslien A, Vasovic V, Mathiesen G, Fredriksen L, Westby P, Eijsink VG, Peng Q, Sioud M (2015)
Recombinant Lactobacillus plantarum induces immune responses to cancer testis antigen NY-ESO-1 and maturation of dendritic cells
Hum Vaccin Immunother, 11 (11), 2664-73
DOI 10.1080/21645515.2015.1056952, PubMed 26185907

Sioud M, Mobergslien A, Sæbøe-Larssen S (2015)
Immunosuppressive factor blockade in dendritic cells via siRNAs results in objective clinical responses
Methods Mol Biol, 1218, 269-76
DOI 10.1007/978-1-4939-1538-5_16, PubMed 25319657

Sioud M, Westby P, Olsen JK, Mobergslien A (2015)
Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells
Mol Ther Methods Clin Dev, 2, 15043
DOI 10.1038/mtm.2015.43, PubMed 26605373

Publications 2013

Mobergslien A, Sioud M (2013)
Exosome-derived miRNAs and cellular miRNAs activate innate immunity
J Innate Immun, 6 (1), 105-10
DOI 10.1159/000351460, PubMed 23774807

Sioud M, Saebøe-Larssen S, Hetland TE, Kaern J, Mobergslien A, Kvalheim G (2013)
Silencing of indoleamine 2,3-dioxygenase enhances dendritic cell immunogenicity and antitumour immunity in cancer patients
Int J Oncol, 43 (1), 280-8
DOI 10.3892/ijo.2013.1922, PubMed 23620105

Sioud M, Skorstad G, Mobergslien A, Sæbøe-Larssen S (2013)
A novel peptide carrier for efficient targeting of antigens and nucleic acids to dendritic cells
FASEB J, 27 (8), 3272-83
DOI 10.1096/fj.12-224758, PubMed 23671272

Publications 2012

Sioud M, Mobergslien A (2012)
Efficient siRNA targeted delivery into cancer cells by gastrin-releasing peptides
Bioconjug Chem, 23 (5), 1040-9
DOI 10.1021/bc300050j, PubMed 22443209

Sioud M, Mobergslien A (2012)
Selective killing of cancer cells by peptide-targeted delivery of an anti-microbial peptide
Biochem Pharmacol, 84 (9), 1123-32
DOI 10.1016/j.bcp.2012.08.002, PubMed 22922046

Publications 2011

Mobergslien A, Sioud M (2011)
Galectin-1 and -3 gene silencing in immature and mature dendritic cells enhances T cell activation and interferon-γ production
J Leukoc Biol, 91 (3), 461-7
DOI 10.1189/jlb.0711361, PubMed 22167721

Publications 2010

Mobergslien A, Sioud M (2010)
Optimized protocols for siRNA delivery into monocytes and dendritic cells
Methods Mol Biol, 629, 71-85
DOI 10.1007/978-1-60761-657-3_5, PubMed 20387143

Sioud M, Mobergslien A, Boudabous A, Fløisand Y (2010)
Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation
Scand J Immunol, 71 (4), 267-74
DOI 10.1111/j.1365-3083.2010.02378.x, PubMed 20384870

Sioud M, Mobergslien A, Boudabous A, Fløisand Y (2010)
Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins
Int J Oncol, 38 (2), 385-90
DOI 10.3892/ijo.2010.869, PubMed 21165555

Feb 13, 2009 Page visits: 4323